Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.
Prothea Technologies has raised $13.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Prothea Technologies's investors include Earlybird Venture Capital, Merieux Equity Partners, NRW.BANK, Old College Capital.
Prothea Technologies is headquartered in Edinburgh, United Kingdom.
Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.
Prothea Technologies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prothea Technologies — Funding & Investors." VCBacked, April 9, 2024, https://www.vcbacked.co/company/prothea-technologies. Accessed September 14, 2026.
VCBacked. (2024). Prothea Technologies — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/prothea-technologies
{{cite web |title=Prothea Technologies — Funding & Investors |url=https://www.vcbacked.co/company/prothea-technologies |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated